shutterstock_235920349

GSK offers concessions ahead of planned venture with Pfizer

pharmafile | June 21, 2019 | News story | Medical Communications, Sales and Marketing |  GSK, Pfizer, pharma 

The European Commission has said that GlaxoSmithKline has offered concessions to address concerns relating to the British multinational’s planned joint venture with Pfizer’s consumer health business.

The EU competition enforcer will make its decision as to whether to accept the proposed merger, demand further concessions or open a full-scale investigation into the deal, by 10 July.

The concessions come as GSK began to sell off some of its consumer healthcare products ahead of the folding of its consumer healthcare brands into a joint venture with Pfizer. The deal was announced in December last year.

Advertisement

The agreement will see the two firms form a “premier global consumer healthcare company.” Pfizer will own 32% of the new consumer healthcare business. GSK will own the rest.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

The Gateway to Local Adoption Series

Latest content